medicationPrescription only (US)Selegiline (Eldepryl, Zelapar, and the transdermal Emsam formulation for depression) is FDA-approved, with the oral Parkinson-disease indication used as adjunctive therapy to levodopa/carbidopaEarly meta-analytic concern about a mortality signal with selegiline plus levodopa was not confirmed by the longer randomized extension trial cited here
SelegilineBenefits, Dosage & Interactions
Also known as: Deprenyl, Eldepryl
Selegiline, also known by its brand names Deprenyl and Eldepryl, is a medication primarily prescribed for the treatment of Parkinson's disease and, in some formulations, for major depressive disorder. It belongs to a class of drugs called selective monoamine oxidase B (MAO-B) inhibitors.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 1 human randomized trial and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
1 human randomized trial and regulatory approval on file.
Plasma half-life
1.5–2 h
Typical timing
morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Selegiline in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Selegiline entry is written from. Each number matches an inline marker above.
- [1]Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysisOlanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, et al. · Neurology · 1998 · Peer-reviewed · PMID 9748034
- [2]Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialShoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, et al. · Annals of Neurology · 2002 · Peer-reviewed · PMID 12112107
How to track Selegiline doses
Tracking Selegiline well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log Selegiline with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is morning. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run Selegiline through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 1.5 h, effects and timing shifts show up over days rather than instantly. Review Selegiline alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg
- Time of day
- Taken / skipped / delayed
- Any side effects or notable changes
References & Evidence
Sources on this page that document Selegiline dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Selegiline?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Selegiline, also known by its brand names Deprenyl and Eldepryl, is a medication primarily prescribed for the treatment of Parkinson's disease and, in some formulations, for major depressive disorder. It belongs to a class of drugs called selective monoamine oxidase B (MAO-B) inhibitors. MAO-B is an enzyme that breaks down dopamine in the brain. By inhibiting this enzyme, selegiline helps to increase and prolong the effects of dopamine, which is beneficial in conditions associated with dopamine deficiency.
Selegiline was first synthesized in 1961. Its use in Parkinson's disease began after studies demonstrated its ability to enhance the effects of levodopa, a common Parkinson's medication. For depression, a transdermal patch formulation allows for different pharmacological effects due to altered metabolism and distribution compared to oral forms (FDA label). Oral selegiline is non-controlled, but dose is user-directed and must be set by a licensed clinician. The half-life of selegiline is approximately 10 hours, but its pharmacological effects can persist longer due to the irreversible inhibition of MAO-B, meaning new enzyme molecules must be synthesized to restore full MAO-B activity (DrugBank).
What does the research say about Selegiline?
Tap a section to expand.
Selegiline exerts its primary therapeutic effects by selectively inhibiting monoamine oxidase B (MAO-B). MAO-B is an enzyme predominantly found in the brain, responsible for the breakdown of dopamine. By inhibiting MAO-B, selegiline reduces the metabolic degradation of dopamine in the synapse, thereby increasing the availability and prolonging the action of dopamine in the central nervous system (DrugBank, PubChem).
At therapeutic doses used for Parkinson's disease, selegiline's inhibition of MAO-B is considered highly selective. However, at higher doses, its selectivity can diminish, and it may begin to inhibit monoamine oxidase A (MAO-A) as well. MAO-A is involved in the metabolism of other neurotransmitters like serotonin and norepinephrine. This loss of selectivity at higher doses is clinically significant because MAO-A inhibition can lead to serious interactions with certain foods (tyramine-containing foods) and medications.
Selegiline is metabolized in the liver into several active metabolites, including L-amphetamine and L-methamphetamine. While these metabolites are pharmacologically active, their contribution to the overall therapeutic effects and side effect profile of selegiline is generally considered minor at standard clinical doses compared to the MAO-B inhibition itself (FDA label). The exact mechanism by which selegiline exerts antidepressant effects when administered via transdermal patch for depression is thought to involve both MAO-A and MAO-B inhibition within the brain, while minimizing systemic MAO-A inhibition that could lead to dietary restrictions (Mayo Clinic).
Source for this section: Sources for How does Selegiline work?: Jumps to this entry in the sources and references list at the end of the page.
Selegiline is primarily recognized for its benefits in the management of Parkinson's disease and, in certain formulations, for major depressive disorder.
* **Parkinson's Disease Monotherapy:** In early Parkinson's disease, selegiline may be used as a monotherapy to delay the need for levodopa treatment. It helps to alleviate some motor symptoms by increasing dopamine levels in the brain (Mayo Clinic).
* **Adjunctive Therapy in Parkinson's Disease:** When used in conjunction with levodopa-carbidopa therapy, selegiline can help reduce 'wearing-off' phenomena and 'off' times, where the effects of levodopa diminish before the next dose. By extending the availability of dopamine, it can improve motor fluctuations and overall motor function (NIH NLM Bookshelf).
* **Delaying Disease Progression (controversial):** Early studies suggested a neuroprotective effect, potentially slowing the progression of Parkinson's disease. However, more extensive clinical trials have largely failed to definitively confirm this neuroprotective benefit, and it remains a topic of ongoing research and discussion among clinicians (Cochrane Review).
* **Major Depressive Disorder:** A transdermal patch formulation of selegiline is approved for the treatment of major depressive disorder. This route of administration is designed to deliver selegiline directly into the systemic circulation, allowing for brain MAO-A and MAO-B inhibition linked to antidepressant effects, while potentially reducing the risk of dietary restrictions associated with oral non-selective MAO inhibitors (FDA label).
Evidence supporting the use of selegiline in Parkinson's disease and major depressive disorder comes from various clinical trials and reviews.
For Parkinson's disease, a Cochrane Review examining selegiline monotherapy in early Parkinson's disease found that it led to a small but statistically significant delay in the time to require levodopa therapy. However, the review noted that improvements in overall motor function were modest.
When used as an adjunct to levodopa, clinical studies have demonstrated selegiline's ability to improve motor fluctuations. For instance, studies cited by the FDA label for oral selegiline show reductions in 'off' time and improvements in daily activities for patients experiencing motor fluctuations on levodopa therapy.
The neuroprotective hypothesis of selegiline, suggesting it could slow Parkinson's disease progression, arose from a study known as the DATATOP study. While this study initially showed a delay in the need for levodopa in the selegiline-treated group, subsequent re-evaluation and larger trials, such as the Parkinson's Study Group PRECEPT study, did not definitively confirm a neuroprotective effect. The observed benefit was largely attributed to symptomatic relief (Examine.com).
For major depressive disorder, the transdermal selegiline patch has been shown to be effective in placebo-controlled trials. The FDA approval for this indication is based on findings from trials demonstrating its efficacy in improving depression symptoms (FDA label). These trials indicate that the transdermal route alters the pharmacokinetic profile sufficiently to allow for a broader MAO inhibition without requiring the strict dietary restrictions typically associated with oral non-selective MAO inhibitors.
Selegiline can cause various side effects, which may differ depending on the dose, formulation (oral vs. transdermal patch), and whether it is used alone or with other medications. Common side effects often include:
* **Gastrointestinal:** Nausea, dry mouth, stomach pain, constipation.
* **Neurological/Psychiatric:** Dizziness, insomnia, headache, confusion, hallucinations (especially in Parkinson's patients when used with levodopa), dyskinesia (involuntary movements, particularly with levodopa use), anxiety, vivid dreams.
* **Cardiovascular:** Orthostatic hypotension (a drop in blood pressure upon standing), palpitations.
* **Other:** Rash or skin irritation (with transdermal patch), back pain.
Serotonin syndrome is a rare but serious side effect that can occur when selegiline is combined with other serotonergic drugs (see `do_not_mix_md` section). Symptoms include agitation, hallucinations, rapid heartbeat, fever, sweating, muscle rigidity, and severe nausea or diarrhea (MedlinePlus).
Though generally well-tolerated at prescribed doses, any new or worsening side effects should be reported to a healthcare professional. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Several warnings and precautions are associated with the use of selegiline.
* **Hypertensive Crisis Risk:** Although oral selegiline is generally selective for MAO-B at recommended doses, this selectivity can be lost at higher doses, leading to inhibition of MAO-A. This increases the risk of a hypertensive crisis if tyramine-containing foods are consumed. While the transdermal patch may not require strict dietary restrictions at recommended doses, patients should still be advised about the potential for interaction with very large amounts of tyramine (FDA label).
* **Serotonin Syndrome:** There is a significant risk of developing serotonin syndrome when selegiline is used concurrently with other serotonergic agents, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, and triptans. This condition can be life-threatening and requires immediate medical attention (Mayo Clinic).
* **Exacerbation of Psychosis:** Selegiline, particularly in combination with dopaminergic agents like levodopa, can exacerbate psychotic symptoms, including hallucinations and delusions, in patients with Parkinson's disease or other predispositions.
* **Falls and Dizziness:** Orthostatic hypotension and dizziness are common side effects, especially in elderly patients or those also taking antihypertensive medications, increasing the risk of falls.
* **Melanoma:** Some studies have suggested a potential association between Parkinson's disease and an increased risk of melanoma. It is unclear whether selegiline itself contributes to this risk, but regular skin examinations are recommended (NIH NLM Bookshelf).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Selegiline is contraindicated in certain situations due to potential risks.
* **Hypersensitivity:** Individuals with a known hypersensitivity to selegiline or any component of its formulation should not use it.
* **Concurrent Use of Certain Medications:** Due to the risk of serotonin syndrome or hypertensive crisis, selegiline is absolutely contraindicated with:
* Other MAO inhibitors (e.g., phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue) – a wash-out period is usually required between discontinuing one MAOI and starting another.
* Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).
* Tricyclic antidepressants (TCAs).
* Meperidine and other opioids like tramadol, methadone, propoxyphene, and dextromethorphan.
* St. John's Wort.
* Buspirone.
* **Pheochromocytoma:** Patients with pheochromocytoma, a tumor of the adrenal gland that secretes high levels of catecholamines, should not use selegiline due to the risk of inducing a hypertensive crisis.
* **Severe Renal or Hepatic Impairment:** Caution is advised, and dose adjustments may be necessary in patients with significant liver or kidney dysfunction, as these organs are crucial for selegiline's metabolism and excretion (FDA label).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Combining selegiline with certain substances can lead to severe and potentially life-threatening adverse reactions. It is critical to inform your healthcare provider about all medications, supplements, and dietary habits before starting selegiline.
* **Other Monoamine Oxidase Inhibitors (MAOIs):** Combining selegiline with other MAOIs (e.g., phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue) is strictly contraindicated. This combination can lead to a hypertensive crisis, characterized by dangerously high blood pressure, severe headache, rapid heart rate, and other serious symptoms (MedlinePlus).
* **Serotonergic Drugs:** A wide range of drugs that increase serotonin levels should not be used with selegiline due to the high risk of serotonin syndrome. These include:
* **SSRIs** (e.g., fluoxetine, sertraline, paroxetine, citalopram).
* **SNRIs** (e.g., venlafaxine, duloxetine).
* **Tricyclic Antidepressants** (e.g., amitriptyline, imipramine).
* **Triptans** (used for migraines, e.g., sumatriptan, zolmitriptan).
* **Certain Opioid Analgesics:** Meperidine, tramadol, methadone, propoxyphene, and dextromethorphan.
* **St. John's Wort.**
* **Buspirone.**
* **Stimulants** (e.g., amphetamines, methylphenidate) and **Tetracyclic Antidepressants** (e.g. mirtazapine) can also increase serotonin and noradrenaline levels, requiring caution.
* **Tyramine-rich Foods (at higher doses or with non-selective forms):** Although oral selegiline is selective for MAO-B at typical Parkinson's doses, and the transdermal patch formulation aims to bypass this interaction, higher doses or individual sensitivities can lead to MAO-A inhibition. This can result in a hypertensive crisis upon consumption of foods rich in tyramine, such as aged cheeses, cured meats, fava beans, tap beers, and soy products. Always follow specific dietary guidance from your clinician based on your selegiline prescription (Mayo Clinic).
* **Dopaminergic Agonists (e.g., bromocriptine, pramipexole):** While often used adjunctively in Parkinson's, combining selegiline with high doses of other dopaminergic agents can increase the risk of side effects like dyskinesia, hallucinations, and orthostatic hypotension.
* **Sympathomimetic Agents:** Medications that stimulate the sympathetic nervous system (e.g., decongestants like pseudoephedrine, phenylephrine, or appetite suppressants) can cause a severe increase in blood pressure when combined with selegiline.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
The typical timing for oral selegiline administration is in the morning. This recommendation is often made to minimize the potential for insomnia, which can be a side effect given its activating properties and known active metabolites (L-amphetamine and L-methamphetamine) (FDA label). For this reason, doses are usually taken with breakfast and/or lunch.
For the transdermal patch formulation, it is typically applied once daily, and the specific time of day for application may be less critical regarding insomnia, though consistency in application time is generally advised for maintaining steady drug levels. Patients should always follow their prescribing clinician's specific instructions regarding the timing and application of selegiline, as individual needs and the formulation used may dictate variations in schedule. Selegiline can generally be taken either with or without food, but specific instructions from your clinician should always be followed.
Source for this section: Sources for When should you take Selegiline?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Selegiline?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
| Sertraline | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Escitalopram | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Fluoxetine | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Citalopram | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Paroxetine | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Duloxetine | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Venlafaxine | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Amphetamine Salts | Avoid | Compound pairConfidence: theoretical | MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.Source pending | Do not combine. |
| Lisdexamfetamine | Avoid | Compound pairConfidence: theoretical | MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.Source pending | Do not combine. |
| Methylphenidate | Avoid | Compound pairConfidence: theoretical | MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.Source pending | Do not combine. |
| Dexmethylphenidate | Avoid | Compound pairConfidence: theoretical | MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.Source pending | Do not combine. |
| Synephrine | Avoid | Compound pairConfidence: theoretical | MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.Source pending | Do not combine. |
| Yohimbine HCl | Avoid | Compound pairConfidence: theoretical | MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.Source pending | Do not combine. |
| Hordenine | Avoid | Compound pairConfidence: theoretical | MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.Source pending | Do not combine. |
Frequently asked questions about Selegiline
Yes, Deprenyl is a brand name for the medication selegiline. They refer to the same active compound (PubChem).
No, selegiline does not cure Parkinson's disease. It is a symptomatic treatment that helps manage symptoms by increasing dopamine levels in the brain. It can improve motor function and may delay the need for other medications, but it does not halt or reverse the underlying disease progression (Mayo Clinic).
At standard doses, oral selegiline's MAO-B selectivity usually means strict dietary restrictions for tyramine-rich foods are not necessary. However, at higher doses, or if the transdermal patch is used, there can be a risk of hypertensive crisis with tyramine-containing foods (e.g., aged cheeses, cured meats, fava beans). Always consult your prescribing clinician for specific dietary guidance based on your personal treatment plan and formulation (FDA label).
The effects of selegiline in Parkinson's disease may not be immediately noticeable and can take several weeks of consistent use to become apparent. For depression, particularly with the transdermal patch, it can also take several weeks for the full antidepressant effects to develop, similar to other antidepressant medications (MedlinePlus).
No, selegiline should not be stopped suddenly without medical supervision, especially if you are taking it for depression. Abrupt discontinuation can lead to withdrawal symptoms or a return of symptoms. Your clinician will guide you on a gradual tapering schedule if the medication needs to be discontinued (Mayo Clinic).
As a medication, Selegiline can overlap with other supplements, prescription medicines, hormones and peptides. Because Selegiline is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 1.5 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Selegiline with no sign-up.
Selegiline is typically taken in the morning. The reported plasma half-life is about 1.5 hours, which is what drives how often it is redosed. Amounts for this medication vary by protocol, formulation and individual response, so follow the dose your clinician or the product label specifies.
Whether Selegiline fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Selegiline. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 1.5 hours is why protocols often split Selegiline across the day rather than using a single dose. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Selegiline clears quickly (plasma half-life around 1.5 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Selegiline the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 26758(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/26758
Verify at
Publisher search links for Selegiline. These are places to check the information — they are not citations, so they are not numbered.
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Selegiline?
Plain-text summary, safe to quote verbatim:
Selegiline, also known by its brand names Deprenyl and Eldepryl, is a medication primarily prescribed for the treatment of Parkinson's disease and, in some formulations, for major depressive disorder. It belongs to a class of drugs called selective monoamine oxidase B (MAO-B) inhibitors.
Source: DoseRoutine — https://doseroutine.com/library/selegiline
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Selegiline — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/selegiline
What compounds are similar to Selegiline?
Others in the medication category or studied for the same goals.